FCA
VRDN icon

FinTrust Capital Advisors’s Viridian Therapeutics VRDN Stock Holding History

FinTrust Capital Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-60
Closed -$1 – 1157
2020
Q3 		$1 Buy
+60
New +$894 ﹤0.01% 1118

Other funds holding VRDN

LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FinTrust Capital Advisors's VRDN Position: Q4 2020 in Review

FinTrust Capital Advisors sold out of Viridian Therapeutics (VRDN) in Q4 2020, closing a stake of 60 shares — an estimated $1 sold.

FinTrust Capital Advisors first reported a position in VRDN in Q3 2020 and held it in 1 quarter. The position peaked at $1 in Q3 2020. 22 funds tracked by Wall St. Rank hold VRDN as of Q4 2020.

  • FinTrust Capital Advisors reported no remaining Viridian Therapeutics position as of Q4 2020 after selling out during the quarter.
  • FinTrust Capital Advisors sold 60 Viridian Therapeutics shares in Q4 2020, an estimated $1.
  • FinTrust Capital Advisors first reported a position in Viridian Therapeutics in Q3 2020 and held it in 1 quarter.
  • FinTrust Capital Advisors's Viridian Therapeutics position peaked at $1 in Q3 2020.
  • 22 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2020.

Based on FinTrust Capital Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.